Professor, Emory School of Medicine · Director, Phase I Clinical Trials, Winship Cancer Institute · Opinions are my own · #oncopharm https://t.co/n5vMbsDMdH
Clin pharm: BCMA directed ADC with MMAF maytansinoid payload (less neurotox vs MMAE)
Dose=2.5 mg/kg over 30 mins Q3 wk with art. tears QID throughout rx (avoid contact lenses)
1/
REMS for ocular AEs (blurred vision - sx in 22%, Gr 3/4 in 4%, other exam findings).
No exposure-response relationship (thus dose = 2.5 rather than 3.4).